Although supports such as counseling, case-management, and peer support are important parts of treatment plans for people with an opioid use disorder (OUD), providing buprenorphine should not be tied to their participation in those services, the US Food and Drug Administration (FDA) and Substance Abuse and Mental Health Services Administration (SAMHSA) underscored in a letter to clinicians.
Source: JAMA Online First